Arsenic trioxide, an old drug - A new face;Trójtlenek arsenu, stary lek - Nowe oblicze

Acta Haematologica Polonica

Volumn 35, Issue 1, 2004, Pages 5-14

  Dmoszyńska, Anna ^a,b   Gósrka, Magdalena ^a  

^a Klinika Hematoonkologii   (Poland)

^b Medical University of Lublin Klinika Hematoonkologii i Transplantacji Szpiku AM w Lublinie   (Poland)

Author keywords

Apoptosis; Arsenic trioxide; Hematological malignancies

Indexed keywords

ARSENIC TRIOXIDE;

ANGIOGENESIS; APOPTOSIS; ARTHRITIS; CELL CYCLE; CELL DIFFERENTIATION; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; SYPHILIS; TRYPANOSOMIASIS;

EID: 2942577578     PISSN: 00015814     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Anderson KC, Boise LH, Louie R, Waxman S. Arsenic trioxide in multiple myeloma: rationale and future directions. Cancer J 2002; 8: 12-25.
2. 3) in the treatement of acute promyelocytic leukemia (APL): I dose-dependent dual effects on APL cells. Blood 1997; 89: 3345-3353.
3. Chen Z, Chen G-Q, Shen Z-X, Sun G-L, Tong J-H, Wang Z-Y, Chen S-J. Expanding the use of arsenic trioxide: leukemias and beyond. Semin Hematol 2002, 39: 22-26.
4. Devison K, Mann KK, Miller WH. Arsenic trioxide: mechanism of action. Semin Hematol 2002; 39: 3-7.
5. Dombret H, Fenaux P, Soignet SL, Tallmoa MS. Estabilished practice in the treatement of patients with acute promyelocytic leukemia and introduction of arsenic trioxide as a novel therapy. Semin Hematol 2002; 39: 8-13.
6. Douer D, Hu W, Giralt S, Lill M, DiPersio J. Arsenic trioxide (Trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Oncologist 2003; 8: 132-140.
7. El-Sabban ME, Nasr R, Dbaibo G, Hermine O, Abboushi N, Quignon F, Ameisen JC, Bex F, de The H, Bazarbachi A. Arsenic-interferon-α-triggered apoptosis in HTLV-1 transformed cells is associated with Tax down-regulation and reversal of NF-κ activation. Blood 2000; 96: 2849-2855.
8. Grand JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001; 95: 805-813.
9. Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D, Munshi NC, Waxman S, Anderson KC. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 2002; 1: 851-816.
10. Huang X-J, Wiernik PH, Klein RS, Gallagher RE. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. Med Oncol 1999; 16: 58-64.
11. Hussein MA. Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma. Oncologist 2002; 7: 20-29.
12. Jing Y, Dai J, Chalmers-Redman RME, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94: 2102-2111.
13. Jing Y, Wang L, Xia L, Chen G-Q, Chen Z, Miller YM, Waxman S. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 2001; 97: 264-269.
14. Kapashi P, Takahashi T, Natoli G, Adams SR, Chen Y, Tsien RY, Karin M. Inhibition of NF-κB activation by arsenic through reaction with a critical cysteine in the activation loop of IκB kinase. J Biol Chem 2000; 275: 36062-36066.
15. Kitamura K, Minami Y, Yamamoto K, Akao Y, Kiyoi H, Saito H, Naoe T. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia 2000; 14: 1743-1750.
16. Kwong YL, Au WY, Chim CS, Pang A, Suen C, Liang R. Arsenic trioxide- and idarubicin-induced remission in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study. Am J Haematol 2001; 66: 274-279.
17. Li YM, Broome JD. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 1999; 59: 776-780.
18. List AE. New approaches to the treatement of myelodysplasia. Oncologist 2002; 7: 39-49.
19. Miller WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanism of action ot arsenic trioxide. Cancer Res 2002; 62: 3893-3903.
20. Munshi NC. Arsenic trioxide: an emerging therapy for multiple myeloma. Oncologist 2001; 6: 17-21.
21. Murgo AJ. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the Natonal Cancer Institute cooperative research and development studies. Oncologist 2001; 6: 22-28.
22. Niu Ch, Yan H, Tu T, Sun H-P, Liu J-X, Li X-S, Wu W, Zhang FQ, Chen Y, Zhou L, Li J-M, Zeng X-Y, Yang R-RO, Yuan M-M, Ren M-Y, Gu F-Y, Cao Q, Gu B-W, Su X-I, Chen G-Q, Xiong S-M, Zhang T-D, Waxman S, Wang Z-Y, Chen Z, Hu J, Shen Z-X, Chen S-J. Studies on treatement of acute promyelocytic leukemia with arsenic trioxide: induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315-3324.
23. O'Dwyer ME, La Rosee P, Nimmanapalli R, Bhalla KN. Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide. Semin Hematol 2002; 39: 18-21.
24. Park WH, Seol JG, Kim ES, Hyun JM, Jung ChW, Lee ChC, Kim BK, Lee YY. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 2000; 60: 3065-3071.
25. Perkins Ch, Kim CN, Fang G, Bhalla KN. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL. Blood 2000; 95: 1014-1022.
26. Pucceti E, Guller S, Orleth A, Bruggenolte N, Hoelzer D, Ottmann OG, Ruthardt M. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Res 2000; 60: 3409-3413.
27. Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP, Rafii S. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000; 96: 1525-1530.
28. Rust DM, Soignet SL. Risk/benefit profile of arsenic trioxide. Oncologist 2000; 6: 29-32.
29. Slack JL, Waxman S, Tricot G, Tallman MS, Bloomfield CD. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. Oncologist 2002; 7: 1-13.
30. Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001; 6: 3-10.
31. Zhu Q, Zhang J-W, Zhu H-Q, Shen Y-L, Flexor M, Jia P-M, Yu Y, Cai X, Waxman S, Lanotte M, Chen S-J, Chen Z, Tong J-H. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood 2002; 99: 1014-1022.